Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity

Area of Science:

• Oncology
• Proteomics
• Genomics
• Transcriptomics

Background:

• Proteomics offers potential for personalized cancer treatment.
• Colorectal cancer (CRC) cell line proteomes were analyzed to assess their representation of primary tumors.
• The study investigated the utility of proteomics in predicting therapeutic responses in CRC.

Purpose of the Study:

• To evaluate the extent to which the proteomic landscape of human colorectal cancer (CRC) is maintained in established CRC cell lines.
• To determine the utility of proteomics for predicting therapeutic responses in CRC.
• To integrate proteomic, transcriptomic, and genomic data with drug sensitivity for personalized medicine.

Main Methods:

• Proteomic and transcriptomic analyses were conducted on 44 CRC cell lines.
• Data were compared with primary CRCs (n=95) and normal tissues (n=60).
• Analyses were integrated with genomic and drug sensitivity data.

Main Results:

• CRC cell lines largely mirrored the proteomic aberrations of primary tumors, including intrinsic programs and post-transcriptional regulation signatures.
• Proteomic data demonstrated superior utility in predicting drug sensitivity compared to genomic or transcriptomic measurements.
• Integrative analysis identified CRC proteomic subtype-specific drug responses and potential synergistic or antagonistic drug combinations.

Conclusions:

• Established CRC cell line proteomes are representative of primary tumors.
• Proteomic profiling shows enhanced predictive value for drug sensitivity over genomic and transcriptomic data.
• Integrative proteogenomic analysis underscores the potential of proteome profiling for informing personalized cancer medicine.